Frontier Medicines is a precision medicine company founded in 2018, with headquarters in South San Francisco, CA and Boston, MA, aiming to revolutionize patients' lives by targeting disease-causing proteins previously considered undruggable. The company has established a powerful platform utilizing technologies in chemoproteomics, covalent drug discovery, and machine learning to develop a pipeline of groundbreaking medicines. Their lead program focuses on addressing both the activated and inactive forms of KRAS G12C, a validated driver in several cancers. In 22 February 2024, Frontier Medicines secured an $80.00M Series C investment from notable investors including DCVC, MPM Capital, RA Capital Management, Deerfield Management, Droia Ventures, and Galapagos. With a primary focus on biopharma, biotechnology, and pharmaceuticals, the company's vision to advance science for the defeat of diseases, particularly cancer, reflects their commitment to pushing the boundaries of innovation.
No recent news or press coverage available for Frontier Medicines.